Moderna, Inc. (MRNA) Down 6.3% — Time to Free Up Some Cash?
Moderna, Inc. (MRNA) is giving back ground on Thursday, last changing hands at $233.09 on the NASDAQ — down $15.60 from the prior close of $248.69. The pullback comes just three days after the stock set its 52-week high of $280.80 on November 9, 2026, and leaves shares about 17.0% below that peak. The broader context still shows how far the stock has climbed. MRNA trades more than ten times above the bottom of its 52-week range of $22.28, so today's decline is a retreat from a high level rather than a breakdown in the longer trend.
Roughly 4.68 million shares have traded so far in the session, compared with a 90-day average of about 17.25 million. With the regular session still open, turnover is running at only about 27% of a typical full day.
Why Moderna, Inc. Price is Moving Lower
The decline looks like a "sell-the-news" reaction to Moderna's Analyst Day rather than a broad market retreat. Management raised its 2026 revenue-growth forecast to a range of 15% to 25%, up from a prior outlook of up to 10%, and said gross margin should expand by about 10 percentage points. However, it deferred formal 2027 guidance until its Q4 earnings call. That left investors without the nearer-term financial detail they wanted after a run that took the stock from the low $20s to above $280. By comparison, the Nasdaq was down only 0.35% and the S&P 500 just 0.17% during the afternoon, so the pressure is concentrated in Moderna itself.
The selling is not a response to weak operating results. Moderna's Q3 report on November 6 showed diluted EPS of $0.38, well ahead of the $1.10 loss analysts expected. Revenue came in at $1.313 billion against a $890.3 million consensus, up 29% year over year, and net income swung to $162 million from a $200 million loss a year earlier. The pipeline news was also encouraging. Moderna reported that its Phase 3 melanoma study with Merck (MRK) met its primary endpoint, with the combination reducing the risk of recurrence or death by 42% compared with Keytruda alone.
Those results raised expectations, and that is the problem. With good news already priced in after the recent surge to a 52-week high, the missing 2027 outlook gave holders a reason to take profits. Some other biotech names are also softer today. Roivant Sciences Ltd. is down 3.61% and Revolution Medicines, Inc. has slipped 1.46%, although neither move comes close to the size of Moderna's drop.
What is the Moderna, Inc. Rating - Should I Sell?
Weiss Ratings assigns MRNA a D- rating. The rating was upgraded on 3/12/2026. Current recommendation is Sell. The upgrade earlier this year recognized some improvement, but a D- still marks a risk/reward profile that Weiss considers unfavorable. The stock's strong price performance has not yet been matched by consistent profitability.
The strongest parts of Moderna's profile are its balance sheet and its returns. The Excellent rating on the Solvency Index suggests the company can fund an extensive late-stage pipeline, including the melanoma program with Merck, without financial strain. This matters for a business whose revenue still swings sharply with the respiratory vaccine season. The Excellent Total Return Index reflects a stock that has climbed from $22.28 to a high of $280.80 within a single 52-week window, a rally few large-cap Health Care names have matched.
The weaker scores explain why the overall rating remains at D-. Moderna is rated Very Weak on the Efficiency Index. Its trailing profit margin of -110.45% and EPS of -$7.09 show that one profitable quarter has not offset the losses of the past year, and the negative forward P/E of -35.06 indicates that losses are still expected ahead. The Fair rating on the Growth Index reflects this mix of strength and inconsistency. Revenue growth of 29.23% is solid, but the jump from $94 million in the June quarter to more than $1.2 billion in the September quarter shows how seasonal and lumpy sales remain. The Weak Volatility Index rating is easy to understand on a day when the stock dropped more than 6% after an Analyst Day that raised guidance but held back 2027 targets.
Within the Health Care sector, Moderna sits alongside Natera, Inc. (NTRA, D-), Revolution Medicines, Inc. (RVMD, D-), and Roivant Sciences Ltd. (ROIV, D-). It trails IQVIA Holdings Inc. (IQV, D+) and Zoetis Inc. (ZTS, D+), both of which rate slightly better in Weiss's framework, though still within Sell territory.
About Moderna, Inc.
Moderna, Inc. (MRNA) is a Health Care company focused on developing messenger RNA medicines for patients in the United States, Europe, and international markets. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company operated as Moderna Therapeutics, Inc. until August 2018. Its commercial base is respiratory vaccines. The COVID-19 franchise includes Spikevax and the next-generation mNEXSPIKE, and mRESVIA targets RSV. Seasonal influenza, combination, and pandemic influenza programs extend the respiratory portfolio further.
Beyond respiratory disease, Moderna is building a pipeline across several therapeutic areas. Its latent virus programs target cytomegalovirus, Epstein-Barr virus, and HIV, and its enteric work targets norovirus. Public health vaccines address Zika, Nipah, and Mpox, and the company is also developing a Lyme disease vaccine for bacterial infections. In oncology, the lead asset is intismeran autogene, the individualized cancer therapy developed with Merck, alongside cancer antigen therapy, T-cell engager, and cell therapy enhancer programs. The rare disease pipeline includes therapies for propionic acidemia, methylmalonic acidemia, and cystic fibrosis.
Moderna's main competitive advantage is its mRNA platform, which lets it move from target selection to clinical candidates faster than traditional vaccine development methods. Partnerships extend that reach. Collaborators include Merck & Co., Vertex Pharmaceuticals, immatics N.V., the Defense Advanced Research Projects Agency, the Biomedical Advanced Research and Development Authority, the Institute for Life Changing Medicines, the Bill & Melinda Gates Foundation, and OpenAI. Together they provide scientific, commercial, and government backing across Moderna's infectious disease and oncology programs.
Investor Outlook
Moderna, Inc. (MRNA) carries a Weiss Rating of D- (Sell). Today's pullback shows how much optimism was already built into the shares, despite stronger 2026 guidance and a positive Phase 3 melanoma result. Investors should watch Q4 earnings call for the delayed 2027 outlook, evidence that the promised 10-point gross margin improvement is taking hold, and the regulatory path for the Merck-partnered melanoma therapy. See full rankings of all D- rated Health Care stocks inside the Weiss Stock Screener.
--